JMP Securities Downgrades Allogene Therapeutics to Market Perform
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has downgraded Allogene Therapeutics (NASDAQ:ALLO) from Market Outperform to Market Perform.
January 05, 2024 | 11:27 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Allogene Therapeutics was downgraded by JMP Securities from Market Outperform to Market Perform, potentially impacting investor sentiment.
Downgrades by analysts can lead to a negative short-term reaction in the stock market as they may indicate a less favorable outlook on the company's performance. This downgrade could lead to a decrease in investor confidence and a potential drop in ALLO's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100